REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and... Read More

REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. The pilot program will demonstrate the value of Biotricity's cardiac monitoring... Read More

REDWOOD CITY, CA / ACCESSWIRE / April 2, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues. There are over 1,000... Read More

REDWOOD CITY, CA / ACCESSWIRE / March 28, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership with yet another leading Group Purchasing Organization (GPO). GPOs streamline purchasing processes for medical... Read More

REDWOOD CITY, CA / ACCESSWIRE / March 21, 2024 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, announces it partnership with Health Aid Africa, one of the most highly anticipated charity concerts for healthcare access and awareness. Experience the rhythm of life like never before at the... Read More

Biotricity's AI automation engine has already proven to increase operational efficiency and support growth, evidenced by the Company's recent margin improvement The Healthcare AI Market is projected to soar to $208.2 billion and remote patient monitoring (RPM) market anticipated to reach $96.67 billion by 2030 Biotricity is now expanding its Cardiac AI platform, building anonymized clinical models to support clinical... Read More

REDWOOD CITY, CA / ACCESSWIRE / March 5, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced its partnership with another of the nation's top Group Purchasing Organizations (GPOs). This strategic move solidifies Biotricity's presence in the healthcare landscape and broadly expands market access for the Company in 2024.... Read More

Well Positioned to Enter US $1.56 Billion Canadian Cardiology Devices Market REDWOOD CITY, CA / ACCESSWIRE / February 29, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, proudly announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering... Read More

Topline growth with better quality revenue mix Increase in subscription revenue (fixed) vs usage based revenue (variable), reducing seasonality impact with more predictable revenue Improved margins Lower costs with improved selling expense Stronger path to breakeven REDWOOD CITY, CA / ACCESSWIRE / February 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company... Read More

REDWOOD CITY, CA / ACCESSWIRE / February 19, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John... Read More

Company continues its shift to subscription-based revenue, prioritizing margin improvement and operational efficiency enhancements, on the path to breakeven Management to announce Third Quarter Fiscal 2024 Results at market close on February 20, 2024 REDWOOD CITY, CA / ACCESSWIRE / February 14, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the... Read More

Company's growing data ecosystem supports the development of large data models for its future predictive technologies and Cardiac AI cloud platform Company has analyzed over 360 Billion heartbeats and helped diagnose over 200,000 patients Company is now focused on building predictive AI models to support earlier diagnoses and interventions Existing technologies are used in 500+ centers across the United States REDWOOD CITY,... Read More

Company reports Q2-FY24 revenue grew by 21.4% YOY to $2.9 million; continuing to advance toward positive cashflow Recurring technology fees, customer device sales, remain on an upward trend Reduced SG&A to $3.5 million, down 22% compared to same period last year Gross margins improve significantly to 69% from 54% compared to the same period last year Recurring Technology Fee Revenue - comprised 94.5% of total revenue with a... Read More

Biotricity improves margins while lowering selling expenses and operating losses REDWOOD CITY, CA / ACCESSWIRE / November 10, 2023 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday,... Read More

Company further expands its current product portfolio, making it the most comprehensive Remote Patient and Cardiac Monitoring portfolio globally. Company developed Biotres Pro with critical capability of cellular backup for connectivity Recently filed a patent application for its Biotres device as it seeks to redefine the cardiac care landscape REDWOOD CITY, CA / ACCESSWIRE / October 31, 2023 / Biotricity Inc. (NASDAQ:BTCY)... Read More

REDWOOD CITY, CA / ACCESSWIRE / October 10, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitoring sector of consumer healthcare, today announced its patent filing for the company's Bioheart device. Bioheart, regarded as one of the most innovative wearable heart monitoring solutions and recognized as one of TIME Magazine's Best Inventions of 2022 stands as a... Read More

This release corrects and replaces the headline in the the release that was disseminated October 3, 2023. The reason for this correction is to fix the title which previously stated "patient" rather than the correct word, "PATENT" REDWOOD CITY, CA / ACCESSWIRE / October 4, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare,... Read More

REDWOOD CITY, CA / ACCESSWIRE / October 3, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the filing of a patent application for its groundbreaking Biotres device. This patent protects Biotres' proprietary 3 channel technology, multiple sensors, architecture and compact form factor, a combination that has... Read More

Biotricitys New Digital Presence Reflects Commitment to Innovation in the Healthcare Space. REDWOOD CITY, CA / ACCESSWIRE / September 13, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, announced today the official launch a new digital presence that illustrates more completely the depth of Biotricity technologies and solutions.... Read More

Corporate Impact Report concluded better patient outcomes and substantial cost savings, thus accelerating Company's sales growth REDWOOD CITY, CA / ACCESSWIRE / August 30, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth... Read More

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023. Company reports Q1-FY24 revenue grew by 46.9% YOY to $3.0 million; continuing to advance toward... Read More

REDWOOD CITY, CA / ACCESSWIRE / August 14, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its First Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, August 15, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John... Read More

Company to report robust performance improvements in its operating metrics Record Q1-FY2024 recurring revenue growth Significantly higher margins on technology fees compared to blended margins Strong control over sales and technology expenses through automation and AI REDWOOD CITY, CA / ACCESSWIRE / August 11, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company... Read More

REDWOOD CITY, CA / ACCESSWIRE / July 26, 2023 / The integration of AI technology in healthcare has revolutionized the industry, particularly in the areas of automation, big data analytics, and optimization. AI-powered software is designed to assist healthcare workers by performing tasks that are time-consuming and require high levels of accuracy. For instance, the use of AI in diagnostic imaging allows for faster and more... Read More

Company revolutionizes cardiac preventive care with state-of-the-art AI technology that improves automation, big data analytics and optimization Biotricity expands its Amazon SageMaker feedback system to drive continuous learning from healthcare professionals to further optimize its AI models AI in Healthcare Market is projected to grow to $208.2 billion by 2030 REDWOOD CITY, CA / ACCESSWIRE / July 25, 2023 / Biotricity Inc.... Read More

REDWOOD CITY, CA / ACCESSWIRE / July 21, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing Biotricity that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for... Read More

Company estimates Q1-FY24 revenue to grow YOY by over 40% Recurring technology fees, customer second-device sales, continue to trend higher REDWOOD CITY, CA / ACCESSWIRE / July 6, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today reported a strong start to its Fiscal Year 2024 ending March... Read More

REDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Holdings, Inc. ("Biotricity" or the "Company") (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023. The reverse stock... Read More

Company advancing toward positive cashflow likely by end of CY 2024 Accelerating product sales, and customer re-order revenue, FY23 revenue rose 26% YOY to $9.64 million on 5% lower SG&A of $17.6 million Improving gross margins currently at 57% despite reduced, loss-leader device pricing to boost recurring ‘Technology Fees,' lower customers' cost of entry, and capture market share Recurring Technology Fee revenue - over 90%... Read More

The Company recently announced reaching a record $13 million annualized revenue run rate in April 2023 REDWOOD CITY, CA / ACCESSWIRE / June 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, announced that it will host its Fiscal Year 2023 Financial Results and Business Update Call on Friday, June 30, 2023. Biotricity Founder and... Read More

Company's proprietary AI technology allows for expansion into predictive monitoring and new disease profiling The New England Journal of Medicine article cites AI and its potential for increased healthcare efficiency and insights REDWOOD CITY, CA / ACCESSWIRE / May 23, 2023 / Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer... Read More

Corporate Impact Report concluded better patient outcomes and substantial cost savings for patients using Company's devices REDWOOD CITY, CA / ACCESSWIRE / May 16, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it reached a record $13 million annualized revenue run rate in April -- further extending its growth... Read More

Dr. Waqaas will address, meet with, world leaders and medical innovators on pressing challenges and solutions in global cardiovascular health, digital health and AI REDWOOD CITY, CA / ACCESSWIRE / May 10, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced that its Founder & CEO Waqaas Al-Siddiq will be speaking at the... Read More

REDWOOD CITY, CA / ACCESSWIRE / April 19, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it reached a record $12 million annualized revenue run rate in March 2023. Based on preliminary month-to-date results and internal projections, the Company remains excited regarding potential top line revenue growth in... Read More

"Inducing Better Patient Outcomes, Substantial Cost Savings" REDWOOD CITY, CA / ACCESSWIRE / April 11, 2023 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, has released its first Corporate Impact Report - revealing that the company's remote, clinical-grade diagnostic devices are inducing "better patient outcomes and substantial cost... Read More

Highlights Several Major Operating Milestones Since FY22 REDWOOD CITY, CA / ACCESSWIRE / March 7, 2023 / Biotricity, Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has not only been establishing a significant market footprint through its robust revenue growth but also reshaping its marketplace through continuous pioneering innovation. Today, Biotricity... Read More

Revenue Up 27.4% YOY Enviable 98% Customer Retention Rate Drives Subscription Recurring Rev Growth Two Major Distribution Agreements Implemented Net Loss Narrowed by One Third as Company Targets Positive Cash Flow Investor Teleconference Scheduled Today for 4:30 ET REDWOOD CITY, CA / ACCESSWIRE / February 14, 2023 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare... Read More

REDWOOD CITY, CA / ACCESSWIRE / February 9, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call on Tuesday, February 14 th , 2023 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter. Financial Results Conference Call Additional details are available under the... Read More

REDWOOD CITY, CA / ACCESSWIRE / February 3, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is excited to announce that it is one of only eight companies selected to present at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference (ISC), being held in Dallas, TX. The showcase is... Read More

REDWOOD CITY, CA / ACCESSWIRE / January 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of... Read More

REDWOOD CITY, CA / ACCESSWIRE / January 23, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced today that Company CEO Waqaas Alsiddiq has been invited to present at the Healthcare IT Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, January 25th, 2023 at 8:15 a.m. ET. Please join us for the... Read More

REDWOOD CITY, CA / ACCESSWIRE / January 17, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced it has signed an agreement with a leading group ‎purchasing organization ("GPO") for national distribution of its cardiac monitoring solutions, Bioflux® and Biotres TM . Both Bioflux and Biotres are designed for cardiologists to diagnose... Read More

Designed to support revenue growth by expanding biotres form factors for the early detection of cardiac arrhythmias in the $5 billion-dollar holter monitor market REDWOOD CITY, CA / ACCESSWIRE / December 12, 2022 / Biotricity, Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it made a 510(k) submission to the U.S. Food and Drug... Read More